Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy fo… Read more
Wuhan Hiteck Biological Pharma Co Ltd (300683) - Net Assets
Latest net assets as of September 2025: CN¥2.24 Billion CNY
Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) has net assets worth CN¥2.24 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.64 Billion) and total liabilities (CN¥393.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.24 Billion |
| % of Total Assets | 85.09% |
| Annual Growth Rate | 22.67% |
| 5-Year Change | 39.81% |
| 10-Year Change | 304.12% |
| Growth Volatility | 45.5 |
Wuhan Hiteck Biological Pharma Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
The table below shows the annual net assets of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.41 Billion | -3.36% |
| 2023-12-31 | CN¥2.50 Billion | +6.87% |
| 2022-12-31 | CN¥2.34 Billion | -0.34% |
| 2021-12-31 | CN¥2.34 Billion | +35.83% |
| 2020-12-31 | CN¥1.72 Billion | -2.02% |
| 2019-12-31 | CN¥1.76 Billion | +2.98% |
| 2018-12-31 | CN¥1.71 Billion | +4.04% |
| 2017-12-31 | CN¥1.64 Billion | +133.61% |
| 2016-12-31 | CN¥703.35 Million | +17.86% |
| 2015-12-31 | CN¥596.76 Million | +11.21% |
| 2014-12-31 | CN¥536.59 Million | +110.72% |
| 2013-12-31 | CN¥254.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Wuhan Hiteck Biological Pharma Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 160.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥370.10 Million | 15.47% |
| Common Stock | CN¥130.89 Million | 5.47% |
| Other Components | CN¥1.89 Billion | 79.05% |
| Total Equity | CN¥2.39 Billion | 100.00% |
Wuhan Hiteck Biological Pharma Co Ltd Competitors by Market Cap
The table below lists competitors of Wuhan Hiteck Biological Pharma Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wilmington plc
PINK:WMGTF
|
$347.37 Million |
|
Surfilter Network Technology Co Ltd
SHE:300311
|
$347.41 Million |
|
Construtora Tenda S.A
SA:TEND3
|
$347.47 Million |
|
Bomesc Offshore Engineering Co
SHG:603727
|
$347.54 Million |
|
Fairfax Financial Holdings Ltd Pfd Shs Ser F 5 Yr Rate Reset
PINK:FXFHF
|
$347.35 Million |
|
Djurslands Bank
CO:DJUR
|
$347.29 Million |
|
Digiworld Corp
VN:DGW
|
$347.19 Million |
|
Attica Bank S.A.
AT:TATT
|
$347.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wuhan Hiteck Biological Pharma Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,478,155,270 to 2,391,790,341, a change of -86,364,929 (-3.5%).
- Net loss of 69,348,658 reduced equity.
- Dividend payments of 1,761,277 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-69.35 Million | -2.9% |
| Dividends Paid | CN¥1.76 Million | -0.07% |
| Other Changes | CN¥-15.25 Million | -0.64% |
| Total Change | CN¥- | -3.49% |
Book Value vs Market Value Analysis
This analysis compares Wuhan Hiteck Biological Pharma Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.82x to 1.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥3.94 | CN¥34.77 | x |
| 2014-12-31 | CN¥7.73 | CN¥34.77 | x |
| 2015-12-31 | CN¥7.79 | CN¥34.77 | x |
| 2016-12-31 | CN¥9.01 | CN¥34.77 | x |
| 2017-12-31 | CN¥18.96 | CN¥34.77 | x |
| 2018-12-31 | CN¥16.43 | CN¥34.77 | x |
| 2019-12-31 | CN¥16.95 | CN¥34.77 | x |
| 2020-12-31 | CN¥16.53 | CN¥34.77 | x |
| 2021-12-31 | CN¥21.85 | CN¥34.77 | x |
| 2022-12-31 | CN¥18.92 | CN¥34.77 | x |
| 2023-12-31 | CN¥19.07 | CN¥34.77 | x |
| 2024-12-31 | CN¥18.28 | CN¥34.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wuhan Hiteck Biological Pharma Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.69%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.23x
- Recent ROE (-2.90%) is below the historical average (8.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 30.68% | 21.81% | 0.81x | 1.74x | CN¥52.34 Million |
| 2014 | 20.56% | 20.03% | 0.68x | 1.50x | CN¥56.46 Million |
| 2015 | 13.98% | 12.27% | 0.78x | 1.46x | CN¥23.74 Million |
| 2016 | 22.54% | 20.37% | 0.74x | 1.49x | CN¥87.37 Million |
| 2017 | 8.70% | 18.98% | 0.39x | 1.17x | CN¥-21.25 Million |
| 2018 | 5.54% | 15.93% | 0.27x | 1.27x | CN¥-75.82 Million |
| 2019 | 3.60% | 10.16% | 0.29x | 1.24x | CN¥-112.19 Million |
| 2020 | -1.46% | -4.77% | 0.24x | 1.28x | CN¥-195.89 Million |
| 2021 | 1.19% | 4.50% | 0.23x | 1.16x | CN¥-204.79 Million |
| 2022 | -0.61% | -2.04% | 0.25x | 1.17x | CN¥-245.07 Million |
| 2023 | -4.88% | -20.06% | 0.20x | 1.20x | CN¥-368.64 Million |
| 2024 | -2.90% | -10.69% | 0.22x | 1.23x | CN¥-308.53 Million |
Industry Comparison
This section compares Wuhan Hiteck Biological Pharma Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wuhan Hiteck Biological Pharma Co Ltd (300683) | CN¥2.24 Billion | 30.68% | 0.18x | $347.36 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |